이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

C-MER Medical Holdings 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dennis Lam

최고 경영자

HK$6.0m

총 보상

CEO 급여 비율	95.7%
CEO 임기	no data
CEO 소유권	0.9%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dennis Lam 의 보수는 C-MER Medical Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	HK$63m
Mar 31 2024	n/a	n/a	HK$63m
Dec 31 2023	HK$6m	HK$6m	HK$62m
Sep 30 2023	n/a	n/a	HK$28m
Jun 30 2023	n/a	n/a	-HK$7m
Mar 31 2023	n/a	n/a	-HK$14m
Dec 31 2022	HK$6m	HK$6m	-HK$22m
Sep 30 2022	n/a	n/a	HK$545k
Jun 30 2022	n/a	n/a	HK$23m
Mar 31 2022	n/a	n/a	HK$22m
Dec 31 2021	HK$6m	HK$6m	HK$22m
Sep 30 2021	n/a	n/a	HK$25m
Jun 30 2021	n/a	n/a	HK$28m
Mar 31 2021	n/a	n/a	HK$11m
Dec 31 2020	HK$4m	HK$4m	-HK$6m
Sep 30 2020	n/a	n/a	-HK$10m
Jun 30 2020	n/a	n/a	-HK$13m
Mar 31 2020	n/a	n/a	HK$14m
Dec 31 2019	HK$1m	HK$1m	HK$41m
Sep 30 2019	n/a	n/a	HK$53m
Jun 30 2019	n/a	n/a	HK$64m
Mar 31 2019	n/a	n/a	HK$53m
Dec 31 2018	HK$1m	HK$1m	HK$43m
Sep 30 2018	n/a	n/a	HK$35m
Jun 30 2018	n/a	n/a	HK$27m
Mar 31 2018	n/a	n/a	HK$31m
Dec 31 2017	HK$4m	HK$3m	HK$40m

보상 대 시장: Dennis 의 총 보상 ($USD 771.01K )은 Hong Kong 시장( $USD 358.97K ).

보상과 수익: Dennis 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dennis Lam (64 yo)

no data

테뉴어

HK$6,018,000

보상

Dr. Shun Chiu Lam, JP, also known as Dennis, serves as Chairman and Chief Executive Officer of C-MER Medical Holdings Limited (formerly known as C-MER Eye Care Holdings Limited). Dr. Lam is also a director...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shun Chiu Lam	Chairman & CEO	no data	HK$6.02m	0.93% HK$ 27.9m
Xiaoting Li	Executive Director	7.3yrs	HK$3.81m	데이터 없음
Yau Wing Lee	Head of Hong Kong Operation & Executive Director	7.3yrs	HK$240.00k	1.06% HK$ 31.8m
Chiu Cheung Ma	Independent Non-Executive Director	6.8yrs	HK$240.00k	데이터 없음
Pak-kuen Auyeung	Independent Vice Chairman of the Board	3.8yrs	HK$759.00k	0.024% HK$ 722.4k
Ke Yin	Independent Non-Executive Director	1.2yrs	HK$120.00k	데이터 없음
Shu Kwan Ip	Independent Non-Executive Director	3.8yrs	HK$240.00k	데이터 없음

5.3yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 3309 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

C-MER Medical Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chairman & CEO recently bought HK$776k worth of stock

Chairman & CEO recently bought HK$841k worth of stock

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 21%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령